• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    46 Biggest Movers From Yesterday

    12/16/21 4:42:57 AM ET
    $ABM
    $ADGI
    $ALZN
    $ASPU
    Diversified Commercial Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABM alert in real time by email

    Gainers

    • Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) gained 34.1% to settle at $12.58 on Wednesday.
    • CMC Materials, Inc. (NASDAQ:CCMP) climbed 33.9% to close at $195.50 on Wednesday after the company announced it will be acquired by Entegris for $6.5 billion in cash and stock.
    • Biofrontera Inc. (NASDAQ:BFRI) shares jumped 26.4% to settle at $6.95 on Wednesday after Benchmark initiated coverage on the stock with a Buy rating and announced a $11 price target.
    • Regional Health Properties, Inc. (NYSE:RHE) gained 23.8% to close at $6.70.
    • Regional Health Props, last month, posted a Q3 loss of $1.25 per share.
    • Gemini Therapeutics, Inc. (NASDAQ:GMTX) rose 23.1% to settle at $2.99 after HC Wainwright & Co initiated coverage on the stock with a Buy rating and a $20 price target.
    • CN Energy Group. Inc. (NASDAQ:CNEY) jumped 22.4% to close at $3.01.
    • Mesoblast Limited (NASDAQ:MESO) climbed 19.2% to settle at $4.97. Mesoblast shares dropped around 28% on Tuesday after the company was notified by Novartis that it has chosen to terminate the agreement with Mesoblast prior to closing.
    • Broadstone Acquisition Corp. (NYSE:BSN) gained 19.1% to close at $10.68.
    • Cabaletta Bio, Inc. (NASDAQ:CABA) jumped 18.2% to settle at $3.97.
    • Ensysce Biosciences, Inc. (NASDAQ:ENSC) surged 17.4% to close at $4.11. Ensysce Biosciences said that the first patients have been enrolled in Phase 1 study of PF614-MPAR, its unique technology platform to provide opioid overdose protection.
    • Trio-Tech International (NYSE:TRT) gained 16.6% to close at $9.42.
    • Aerovate Therapeutics, Inc. (NASDAQ:AVTE) jumped 16.3% to close at $12.34 after the company announced the initiation of its IMPAHCT Phase 2b/Phase 3 trial of AV-101 In Pulmonary Arterial Hypertension.
    • Optical Cable Corporation (NASDAQ:OCC) gained 16.2% to settle at $6.40.
    • Conn's, Inc. (NASDAQ:CONN) rose 16.1% to close at $20.81. Conn's Board of Directors authorized a repurchase program of $150 million of its outstanding stock.
    • Design Therapeutics, Inc. (NASDAQ:DSGN) surged 16% to settle at $20.36.
    • Bird Global, Inc. (NYSE:BRDS) gained 15.7% to close at $8.97.
    • VerifyMe, Inc. (NASDAQ:VRME) jumped 13.7% to close at $3.65.
    • East Stone Acquisition Corporation (NASDAQ:ESSC) gained 12.9% to close at $15.24 after declining 26% on Tuesday.
    • Vir Biotechnology, Inc. (NASDAQ:VIR) gained 12.1% to close at $51.62 after the company announced new preclinical data demonstrating the impact of the significant antigenic shift of the new SARS-CoV-2 Omicron variant.
    • SeaChange International, Inc. (NASDAQ:SEAC) rose 11.9% to close at $1.69 after the company reported better-than-expected Q3 results.
    • Nxt-ID, Inc. (NASDAQ:NXTD) shares rose 11.7% to close at $2.78 after the company said it was awarded U.S. General Services Administration contract to distribute personal emergency response systems to Federal, State and Local government purchasers.
    • Tandem Diabetes Care, Inc. (NASDAQ:TNDM) climbed 10.5% to close at $144.34.
    • Eli Lilly and Company (NYSE:LLY) climbed 10.4% to close at $275.28 after the company issued FY21 EPS guidance above analyst estimates.
    • Borr Drilling Limited (NYSE:BORR) gained 9.2% to close at $1.67 after declining over 4% on Tuesday..
    • Galera Therapeutics, Inc. (NASDAQ:GRTX) gained 7.4% to close at $2.90 after BTIG upgraded the stock from Neutral to Buy and announced a $15 price target. Galera Therapeutics shares jumped around 96% on Tuesday after the company announced the primary endpoint met statistical significance in corrected topline efficacy data of Phase 3 ROMAN trial of avasopasem.


    Check out these big penny stock gainers and losers

    Losers

    • Atai Life Sciences N.V. (NASDAQ:ATAI) dropped 31.9% to close at $6.82 on Wednesday.
    • China Xiangtai Food Co., Ltd. (NASDAQ:PLIN) fell 28.2% to settle at $1.81. The company earlier announced the completion of its first purchase of spot Bitcoin miners worth $7 million.
    • Aspen Group, Inc. (NASDAQ:ASPU) shares declined 27.2% to close at $1.90 on Wednesday after the company reported worse-than-expected Q2 results and cut FY22 guidance.
    • REV Group, Inc. (NYSE:REVG) fell 25.5% to close at $11.87 after the company reported worse-than-expected Q4 EPS and sales results and issued FY22 sales guidance below estimates.
    • Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) shares dipped 25.3% to close at $0.6501 on Wednesday after the company announced tilsotolimod updates. The company said no further enrollment in ILLUMINATE-206 trial is planned at this point.
    • LianBio (NASDAQ:LIAN) fell 21.3% to close at $7.68. LianBio reported a Q3 loss of $0.63 per share.
    • The Oncology Institute, Inc. (NASDAQ:TOI) fell 17.9% to close at $6.25.
    • Alzamend Neuro, Inc. (NASDAQ:ALZN) fell 15.9% to close at $2.59 after jumping 28% on Tuesday.
    • LogicBio Therapeutics, Inc (NASDAQ:LOGC) dropped 15.5% to close at $2.45. Barclays maintained LogicBio Therapeutics with an Overweight and lowered the price target from $24 to $8.
    • Legend Biotech Corporation (NASDAQ:LEGN) shares fell 15.3% to close at $41.14 after the company reported an offering of $300 million in ADSs.
    • Huadi International Group Co., Ltd. (NASDAQ:HUDI) fell 15% to close at $27.62.
    • iSpecimen Inc. (NASDAQ:ISPC) fell 13.3% to close at $10.87.
    • MIND Technology, Inc. (NASDAQ:MIND) shares fell 12.9% to close at $1.55. MIND Technology shares gained 30% on Tuesday after the company reported it entered into a Cooperative Research and Development Agreement with the United States Navy's Naval Surface Warfare Center, Panama City Division.
    • Adagio Therapeutics, Inc. (NASDAQ:ADGI) fell 12.5% to close at $6.35 after Stifel downgraded the stock from Buy to Hold and lowered the price target from $50 to $9. Adagio Therapeutics shares dipped 79% on Tuesday after the company said based on the in vitro findings related to Omicron, it plans to pause patient recruitment in its Phase 2/3 COVID-19 treatment trial at clinical sites in South Africa.
    • Zai Lab Limited (NASDAQ:ZLAB) fell 12.4% to close at $54.90.
    • Cerence Inc. (NASDAQ:CRNC) dropped 11.4% to close at $69.20. Cerence’s board promoted Dr. Stefan Ortmanns to Chief Executive Officer and Director.
    • ABM Industries Incorporated (NYSE:ABM) fell 11% to close at $40.88 as the company reported fourth-quarter revenue growth of 14.2% year-over-year to $1.69 billion, comprised of 7.4% organic growth and 6.8% from acquisition.
    • BeiGene, Ltd. (NASDAQ:BGNE) fell 10.7% to close at $248.56. BeiGene reported authorisation of BRUKINSA (zanubrutinib) from the UK’s MHRA for the treatment of adults with Waldenström’s Macroglobulinemia in Great Britain.
    • Cooper-Standard Holdings Inc. (NYSE:CPS) fell 7.1% to close at $19.71.
    • Nisun International Enterprise Development Group Co., Ltd (NASDAQ:NISN) fell 6.9% to close at $3.50.
    • I-Mab (NASDAQ:IMAB) fell 5% to close at $46.97. I-Mab received IND approval for Phase 1 clinical trial of bispecific antibody TJ-CD4B in solid tumors in China.
    Get the next $ABM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABM
    $ADGI
    $ALZN
    $ASPU

    CompanyDatePrice TargetRatingAnalyst
    Tandem Diabetes Care Inc.
    $TNDM
    1/27/2026$25.00Buy
    TD Cowen
    Legend Biotech Corporation
    $LEGN
    1/22/2026$21.00Buy → Hold
    TD Cowen
    ABM Industries Incorporated
    $ABM
    1/21/2026$47.00Buy → Hold
    Truist
    AtaiBeckley Inc.
    $ATAI
    1/20/2026$11.00Buy
    Guggenheim
    Eli Lilly and Company
    $LLY
    1/7/2026$1250.00Buy
    UBS
    Design Therapeutics Inc.
    $DSGN
    1/7/2026$18.00Outperform
    Oppenheimer
    Legend Biotech Corporation
    $LEGN
    1/7/2026$75.00Outperform
    Oppenheimer
    ABM Industries Incorporated
    $ABM
    12/18/2025$51.00Buy → Neutral
    UBS
    More analyst ratings

    $ABM
    $ADGI
    $ALZN
    $ASPU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen resumed coverage on Tandem Diabetes Care with a new price target

    TD Cowen resumed coverage of Tandem Diabetes Care with a rating of Buy and set a new price target of $25.00

    1/27/26 8:50:26 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Legend Biotech downgraded by TD Cowen with a new price target

    TD Cowen downgraded Legend Biotech from Buy to Hold and set a new price target of $21.00

    1/22/26 8:26:15 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ABM Industries downgraded by Truist with a new price target

    Truist downgraded ABM Industries from Buy to Hold and set a new price target of $47.00

    1/21/26 8:51:36 AM ET
    $ABM
    Diversified Commercial Services
    Consumer Discretionary

    $ABM
    $ADGI
    $ALZN
    $ASPU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP and CFO Smith Tracy G covered exercise/tax liability with 4,341 shares, decreasing direct ownership by 1% to 346,311 units (SEC Form 4)

    4 - OPTICAL CABLE CORP (0001000230) (Issuer)

    2/3/26 4:48:23 PM ET
    $OCC
    Telecommunications Equipment
    Industrials

    Chairman, President and CEO Wilkin Neil D Jr covered exercise/tax liability with 8,000 shares, decreasing direct ownership by 0.77% to 1,035,155 units (SEC Form 4)

    4 - OPTICAL CABLE CORP (0001000230) (Issuer)

    2/3/26 4:47:28 PM ET
    $OCC
    Telecommunications Equipment
    Industrials

    EVP&Pres, LLY USA&Global Capab Yuffa Ilya converted options into 3,394 shares and covered exercise/tax liability with 1,512 shares, increasing direct ownership by 7% to 28,142 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/3/26 4:32:39 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABM
    $ADGI
    $ALZN
    $ASPU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 28, 2025 - FDA Roundup: February 28, 2025

    For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

    2/28/25 5:00:47 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABM
    $ADGI
    $ALZN
    $ASPU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Chang David J. bought $19,888 worth of shares (8,800 units at $2.26) (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:56:58 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President, Science & Tech. Binder Gwendolyn bought $24,763 worth of shares (11,312 units at $2.19), increasing direct ownership by 57% to 31,312 units (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:56:30 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Tomasello Shawn bought $50,322 worth of shares (22,725 units at $2.21) (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:55:49 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABM
    $ADGI
    $ALZN
    $ASPU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    iSpecimen Announces Milestone 2: System Integration and Marketplace Activation Complete

    Live Production Marketplace Now AvailableWoburn, Massachusetts--(Newsfile Corp. - February 6, 2026) - iSpecimen Inc. (NASDAQ:ISPC) today announced the successful completion of Milestone 2, System Integration and Marketplace Activation, marking a pivotal step in the SalesStack digital transformation journey. The milestone delivers a fully integrated, live marketplace that connects customer requests with supplier inventories, enabling streamlined operations, reduced costs, and a foundation for future growth.Chief Executive Officer Ms. Katie Field commented, "This Milestone 2 achievement demonstrates end-to-end system integration, legacy data migration, and activation of a production-ready Sale

    2/6/26 9:30:00 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    iSpecimen Achieves Rapid Procurement Milestone for Influenza Research

    Lexington, Massachusetts--(Newsfile Corp. - February 6, 2026) - iSpecimen Inc. (NASDAQ:ISPC), a leading provider of human biospecimens for research, is proud to announce recent milestones that demonstrate the strength, responsiveness, and reliability of its site network.Over the past several months, iSpecimen has been actively supporting customer research by sourcing high-quality respiratory samples, with a particular focus on influenza. Most recently, iSpecimen successfully collected 500 influenza swab samples in just a few weeks to support a customer research project—demonstrating its ability to respond quickly to time-sensitive research needs. The rapid turnaround and quality of the speci

    2/6/26 8:20:00 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $207B Market Shift: The Race for Fast Track Approval in Oncology

    Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 5, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – The FDA isn't just approving drugs; they are completely reshaping the landscape. In 2025 alone, the agency issued over 50 oncology approvals[1], but the real story is the aggressive pivot toward targeted therapies for high-unmet-need solid tumors. That momentum has accelerated in 2026 with a sudden flurry of expedited designations[2] for RAS inhibitors and rare malignancies. This regulatory velocity creates a clear validation framework, positioning Oncolytics Biotech Inc. (NASDAQ:ONCY), Relay Therapeutics (NASDAQ:RLAY), MAIA Biotechnology (NYSE-A: MAIA), Zai Lab (NASDAQ:

    2/5/26 9:35:00 AM ET
    $AVBP
    $ONCY
    $RLAY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ABM
    $ADGI
    $ALZN
    $ASPU
    SEC Filings

    View All

    iSpecimen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - iSpecimen Inc. (0001558569) (Filer)

    2/6/26 4:05:23 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 6-K filed by Legend Biotech Corporation

    6-K - Legend Biotech Corp (0001801198) (Filer)

    2/6/26 4:00:03 PM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ABM Industries Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - ABM INDUSTRIES INC /DE/ (0000771497) (Filer)

    2/5/26 4:20:33 PM ET
    $ABM
    Diversified Commercial Services
    Consumer Discretionary

    $ABM
    $ADGI
    $ALZN
    $ASPU
    Leadership Updates

    Live Leadership Updates

    View All

    The Oncology Institute Announces Addition of Board Member Mark Stolper

    CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncolog

    1/5/26 8:30:00 AM ET
    $RDNT
    $TOI
    Medical Specialities
    Health Care
    Medical/Nursing Services

    The Oncology Institute Announces Resignation of Board Member Gabe Ling

    CERRITOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Gabe Ling has resigned from the Board of Directors, effective December 1, 2025. A formal search process has been initiated to add new independent directors with complementary healthcare, clinical, and value-based care expertise. "On behalf of the Board of Directors, I want to thank Gabe for his service during an important chapter in The Oncology Institute's development," said Anne McGeorge, Chairman of the Board. "We appreciate the contributions he made throughout his time on the Board and the valua

    12/1/25 8:30:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Tandem Diabetes Care Announces Appointment of Sandra Beaver to Board of Directors

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Sandra Beaver to its board of directors effective November 7, 2025. Ms. Beaver joins the board as an independent director and will serve on the board's Audit Committee and Cybersecurity and Data Oversight Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112460451/en/Sandra Beaver joins Tandem Diabetes Care Board of Directors. "We welcome Sandra to our Board of Directors at this pivotal stage in Tandem's evolution," said John Sheridan, president and CEO. "Sandra is a dynamic finance

    11/12/25 9:00:00 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $ABM
    $ADGI
    $ALZN
    $ASPU
    Financials

    Live finance-specific insights

    View All

    Cerence Delivers Strong Q1 FY26 Results, with Record-Setting Free Cash Flow, Adjusted EBITDA Above Guidance, and Accelerating Technology and Customer Momentum

    Headlines Strong Q1 results with revenue of $115.1 million, including the $49.5M patent license payment; Net cash provided by operating activities of $37.9 million; and free cash flow of $35.6 million - a quarterly record for the Company, reflecting disciplined execution and profitabilityAccelerating innovation and customer momentum for Cerence xUI, with five significant customer programs and the first xUI-powered cars expected to hit roads in 2026; strong reception at CES 2026Advancing toward long-term sustainable growth, supported by cost discipline and debt reduction; Company reaffirms full‑year fiscal 2026 guidance BURLINGTON, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Cerence Inc.

    2/4/26 4:05:00 PM ET
    $CRNC
    Computer Software: Prepackaged Software
    Technology

    Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

    Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound.Q4 2025 EPS increased by 51% to $7.39 on a reported basis and increased by 42% to $7.54 on a non-GAAP basis, both inclusive of $0.52 of acquired IPR&D charges.Regulatory progress included FDA approval of Kwikpen for tirzepatide and an expanded indication for Jaypirca, and submissions for orforglipron for obesity to regulatory authorities in the U.S. and Japan and for obesity and type 2 diabetes in the EU. Pipeline progress included positive Phase 3 results from Taltz and Zepbound used together for adults with active psoriatic arthritis and obesity, orforglipron for people who switched from in

    2/4/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Borr Drilling Limited - Invitation to Webcast and Conference Call for Q4 2025 Results

    HAMILTON, Bermuda, Jan. 30, 2026 /PRNewswire/ -- Borr Drilling Limited (NYSE and Euronext Growth Oslo: BORR) (the "Company") plans to release its financial results for the fourth quarter of 2025 after the close of the New York Stock Exchange on Wednesday, February 18, 2026. A conference call and webcast are scheduled for 09:00 New York time (15:00 CET) on Thursday, February 19, 2026. The earnings report, webcast and accompanying presentation will be available on the Investor Relations section of the Company's website, www.borrdrilling.com. In order to listen to the live presentation, participants may do one of the following: a)    Webcast To access the webcast, please go to the following l

    1/30/26 10:09:00 AM ET
    $BORR
    Oil & Gas Production
    Energy

    $ABM
    $ADGI
    $ALZN
    $ASPU
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Led to the Purchase at Aerovate Therapeutics Inc. on Jun 20?

    Recently, on June 20, 2024, a notable insider purchase was made at Aerovate Therapeutics Inc. Director Ra Capital Management, L.P. bought $1,549,944 worth of shares, acquiring 928,110 units at $1.67 per share as reported in the SEC Form 4. Insider transactions like these are closely watched by investors as they can provide valuable insights into the company's prospects. When analyzing insider transactions, it is essential to look for patterns and trends among multiple transactions to gauge the overall sentiment within the company. Several other SEC Form 4 filings were made around the same time, on June 7, 2024, by various insiders at Aerovate Therapeutics Inc. These included transactions by

    6/21/24 3:23:59 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABM
    $ADGI
    $ALZN
    $ASPU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

    SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)

    12/10/24 9:30:34 PM ET
    $BGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/6/24 4:05:57 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care